The share market can be unpredictable in the short term, but over time, it tends to reward investors who buy great businesses and let compounding do its work.
With that in mind, here are three ASX stocks that might just quietly make you rich if you give them time:
Image source: Getty Images
Macquarie Group Ltd (ASX: MQG)
Often called the millionaire factory, Macquarie Group has earned its reputation as one of Australia's most successful financial institutions.
But it certainly isn't your typical bank, it is a global powerhouse in asset management, infrastructure, and green energy investment.
Macquarie manages hundreds of billions of dollars across infrastructure, renewables, and private equity assets. Its diversified business model means it earns money whether markets rise or fall, and it continues to expand globally as the world transitions to cleaner energy sources.
Ord Minnett is a fan of the investment bank. Earlier this week, it upgraded its shares to a buy rating with a $255.00 price target.
NextDC Ltd (ASX: NXT)
In a world increasingly driven by data, NextDC is quietly powering the digital economy. It owns and operates a network of data centres that host the cloud infrastructure behind everything from video streaming and online shopping to artificial intelligence and financial transactions.
NextDC's facilities are essentially the backbone of digital connectivity. And with the explosion in cloud computing and AI workloads, demand for secure, high-performance data storage is growing exponentially. This bodes well for the future, particularly given how this ASX stock continues to expand aggressively across Australia and Asia.
Macquarie thinks it would be a great stock to buy now. This month, the broker put an outperform rating and $20.90 price target on its shares.
Pro Medicus Ltd (ASX: PME)
Finally, Pro Medicus could be another ASX stock that quietly makes you rich.
It develops medical imaging software used by hospitals and radiology groups around the world to store, view, and analyse digital scans. Its flagship platform is Visage 7, which allows doctors to instantly access high-resolution images across multiple sites, improving efficiency and patient outcomes.
Pro Medicus operates on a high-margin, recurring revenue model that continues to scale globally. Its contracts with major US health networks run for many years, locking in reliable cash flow and delivering some of the best profit margins on the ASX.
The team at Bell Potter is confident that this trend can continue. As a result, this morning it put a buy rating and $320.00 price target on its shares.
